Colorectal cancer is one of the most frequently diagnosed malignancies worldwide. According to the American Cancer Society, approximately 1 in 23 men and 1 in 26 women will develop colorectal cancer in their lifetime. While early-stage colorectal cancer is highly treatable, advanced and aggressive forms often require more than conventional treatments like surgery or chemotherapy.
Recent advances in immunotherapy have introduced powerful alternatives for patients with advanced colorectal cancer, offering new hope for long-term remission and improved quality of life.
Understanding Colorectal Cancer and Its Challenges
The large intestine consists of the colon (divided into the ascending, transverse, descending, and sigmoid sections) and the rectum. Given their structural similarities, cancers originating in one area can easily spread to the other, leading to the common classification of “colorectal cancer.”
Most colorectal cancers fall into two primary categories:
- Adenocarcinomas: These originate in the epithelial cells lining the colon and can spread to other organs if untreated.
- Mucinous adenocarcinomas (MACs): More aggressive than standard adenocarcinomas, these secrete mucus, allowing them to spread faster.
More rare forms include carcinoid tumors, lymphomas, and gastrointestinal stromal tumors (GISTs). These cancers often present challenges in diagnosis and treatment due to their unique behaviors.
For early-stage colorectal cancer, surgery often provides an effective cure. However, once the cancer reaches stage 3 or 4, treatment usually involves a combination of surgery, chemotherapy, and radiotherapy. While chemotherapy protocols like FOLFOX and CapeOx can be effective, they are not always successful, particularly in cases of chemotherapy-resistant tumors or those with high levels of cancer stem cells.
Moreover, repeated surgeries and aggressive treatments can significantly impact a patient’s quality of life. In cases of recurrence, conventional methods often fail, making alternative approaches necessary.
Immunotherapy: A Game-Changer for Colorectal Cancer
Immunotherapy harnesses the body’s immune system to recognize and destroy cancer cells. It is particularly promising for patients with chemotherapy-resistant or metastatic colorectal cancer. Unlike traditional treatments, which often cause significant side effects, immunotherapy aims to eradicate cancer cells while preserving healthy tissue.
At Biotherapy International, we focus on cutting-edge immunotherapy techniques designed to eliminate cancer at its root. These include:
Oncolytic Virus Therapy for Colorectal Cancer
Oncolytic viruses selectively target and destroy cancer cells while leaving healthy cells untouched. These viruses infiltrate tumors, replicate inside cancer cells, and trigger apoptosis (programmed cell death). As the infected cancer cells rupture, they release new virus particles, which then attack neighboring cancer cells.
Administered intravenously or via direct injection into the tumor, oncolytic viruses can be highly effective for colorectal cancer patients who have not responded to chemotherapy. Many of our patients have shown remarkable improvement after receiving this therapy.
Personalized Cancer Vaccines
Cancer vaccines are one of the most innovative approaches in colorectal cancer immunotherapy. These vaccines use a patient’s tumor cells, modified to enhance immune recognition, to train the immune system to identify and destroy cancerous cells.
The process involves isolating tumor tissue, engineering it with oncolytic viruses or immune-stimulating agents (such as Coley’s toxin), and reintroducing it into the patient’s body. This activates the immune system, leading to a targeted and aggressive response against cancer cells. Patients with access to frozen tumor samples can particularly benefit from this approach, as it allows for a fully personalized immunotherapy regimen.
ATACK Method: Targeted Killer Cells for Colorectal Cancer
The Allogeneic Targeted Activated Cancer Killer cells (ATACK method) is designed to induce a strong attack against cancer cells using mismatched donor-derived killer cells, including T cells, NK cells, and NKT cells. These cells target tumors that have resisted conventional treatments.
Monoclonal antibodies help guide these killer cells to specific cancer antigens, triggering a rejection-like response that eliminates tumors more effectively than a patient’s own immune cells. This method is particularly effective for resistant or recurrent cancers, as it bypasses the limitations of self-tolerance.
Unlike conventional immunotherapies that rely solely on activating the patient’s own immune cells, ATACK delivers a more aggressive response by using donor-derived cells that are primed before infusion. Once in the body, these cells continue to be stimulated by IL-2, boosting their anti-cancer activity and enhancing the patient’s natural immune defense.
Achieving Long-Term Remission with Immunotherapy
For patients diagnosed with early-stage colorectal cancer, conventional treatments may be sufficient. However, for aggressive or recurrent cases, immunotherapy provides the best chance for extended survival and even complete remission.
Unlike chemotherapy, which can weaken the immune system over time, immunotherapy strengthens the body’s natural defenses, making future recurrences less likely. This is especially crucial for patients with aggressive cancer subtypes like signet ring cell adenocarcinoma, which has a five-year survival rate of just 9%.
A Future Without Colorectal Cancer
Integrating immunotherapy into colorectal cancer treatment represents a major step toward achieving long-term remission while preserving patients’ quality of life. At Biotherapy International, we continuously refine our immunotherapy techniques to offer patients the most effective, personalized treatment options available.
For those facing advanced or recurrent colorectal cancer, immunotherapy offers a renewed sense of hope. By targeting cancer at its source and empowering the immune system to fight back, these advanced therapies provide the possibility of not just extending life, but restoring health and well-being.
